Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Waldenström Macroglobulinemia — Treatment

First-line Second-line SECOND-LINE Waldenström macroglobulinemia (symptomatic) Hyperviscosity Frontline Relapsed / refractory Emergent Plasmapheresis before/with systemic therapy BTKi Zanubrutinib / ibrutinib ASPEN ↗ Chemo-IO Bendamustine + rituximab fixed-duration Switch Alternate BTKi / BR / proteasome inhibitor per prior therapy